share_log

Cybin | SC 13G: Statement of acquisition of beneficial ownership by individuals-Deep Track Capital, LP(7.65%),Deep Track Biotechnology Master Fund, Ltd.(7.65%), etc.

Cybin | SC 13G: Statement of acquisition of beneficial ownership by individuals-Deep Track Capital, LP(7.65%),Deep Track Biotechnology Master Fund, Ltd.(7.65%), etc.

Cybin | SC 13G：超过5%持股股东披露文件-Deep Track Capital, LP(7.65%),Deep Track Biotechnology Master Fund, Ltd.(7.65%)等
SEC announcement ·  03/22 16:08
Moomoo AI 已提取核心信息
On March 14, 2024, a Schedule 13G filing was made with the United States Securities and Exchange Commission by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin, indicating a significant ownership stake in Cybin Inc. The filing revealed that the reporting entities collectively hold 58,139,535 common shares of Cybin Inc., representing 7.65% of the company's class of securities. The shares are held with shared voting and dispositive power. The filing, made under Rule 13d-1(c), is not intended to effect a change in control of Cybin Inc. but is a standard disclosure for entities owning more than five percent of a class of a company's shares. The principal business office addresses for the reporting persons are located in Greenwich, CT, and George Town, Cayman Islands, with citizenships in Delaware, Cayman Islands, and the United States, respectively. The filing was certified by David Kroin, the Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, and Director of Deep Track Biotechnology Master Fund, Ltd.
On March 14, 2024, a Schedule 13G filing was made with the United States Securities and Exchange Commission by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin, indicating a significant ownership stake in Cybin Inc. The filing revealed that the reporting entities collectively hold 58,139,535 common shares of Cybin Inc., representing 7.65% of the company's class of securities. The shares are held with shared voting and dispositive power. The filing, made under Rule 13d-1(c), is not intended to effect a change in control of Cybin Inc. but is a standard disclosure for entities owning more than five percent of a class of a company's shares. The principal business office addresses for the reporting persons are located in Greenwich, CT, and George Town, Cayman Islands, with citizenships in Delaware, Cayman Islands, and the United States, respectively. The filing was certified by David Kroin, the Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, and Director of Deep Track Biotechnology Master Fund, Ltd.
2024年3月14日，Deep Track Capital, LP、Deep Track Biotechnology Master Fund, L.和David Kroin向美国证券交易委员会提交了附表13G的文件，表明Cybin Inc.拥有大量所有权。该文件显示，申报实体共持有Cybin Inc.的58,139,535股普通股，占该公司证券类别的7.65％。这些股份以共同的投票权和处置权持有。该文件是根据第13d-1（c）条提交的，无意变更对Cybin Inc.的控制权，而是对拥有某类公司股份超过5％的实体的标准披露。申报人的主要办公地址位于康涅狄格州格林威治和开曼群岛乔治城，国籍分别位于特拉华州、开曼群岛和美国。该文件由Deep Track Capital, LP投资顾问普通合伙人管理成员兼Deep Track Biotechnology Master Fund, Ltd董事大卫·克罗因认证。
2024年3月14日，Deep Track Capital, LP、Deep Track Biotechnology Master Fund, L.和David Kroin向美国证券交易委员会提交了附表13G的文件，表明Cybin Inc.拥有大量所有权。该文件显示，申报实体共持有Cybin Inc.的58,139,535股普通股，占该公司证券类别的7.65％。这些股份以共同的投票权和处置权持有。该文件是根据第13d-1（c）条提交的，无意变更对Cybin Inc.的控制权，而是对拥有某类公司股份超过5％的实体的标准披露。申报人的主要办公地址位于康涅狄格州格林威治和开曼群岛乔治城，国籍分别位于特拉华州、开曼群岛和美国。该文件由Deep Track Capital, LP投资顾问普通合伙人管理成员兼Deep Track Biotechnology Master Fund, Ltd董事大卫·克罗因认证。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息